The prospect of approving Cervarix for a broad audience in the U.S. may be leading to a bad case of cold feet at the FDA. The agency's Office of Vaccine Research & Review deputy director Florence Houn has expressed her own concerns that the agency doesn't fully understand the mechanism of adjuvants in immune response. Report